Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 27,197 shares of the firm’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $73.57, for a total value of $2,000,883.29. Following the sale, the senior vice president now directly owns 47,363 shares in the company, valued at approximately $3,484,495.91. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of Baxter International opened at $73.80 on Friday, Marketbeat Ratings reports. Baxter International Inc has a twelve month low of $58.81 and a twelve month high of $75.62. The company has a market capitalization of $39.17 billion, a price-to-earnings ratio of 29.76, a P/E/G ratio of 1.89 and a beta of 0.81. The company has a current ratio of 2.63, a quick ratio of 2.03 and a debt-to-equity ratio of 0.39.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.08. Baxter International had a return on equity of 15.70% and a net margin of 7.75%. The company had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same period last year, the business posted $0.58 EPS. The company’s revenue was up 8.2% on a year-over-year basis. equities analysts expect that Baxter International Inc will post 2.89 EPS for the current year.
Hedge funds have recently made changes to their positions in the business. Maverick Capital Ltd. grew its stake in shares of Baxter International by 91.4% in the 4th quarter. Maverick Capital Ltd. now owns 108,210 shares of the medical instruments supplier’s stock valued at $6,995,000 after purchasing an additional 51,670 shares during the last quarter. BancorpSouth Bank purchased a new position in shares of Baxter International in the 4th quarter valued at approximately $693,000. 180 Wealth Advisors LLC purchased a new position in shares of Baxter International in the 4th quarter valued at approximately $480,000. Signaturefd LLC boosted its stake in shares of Baxter International by 31.9% in the fourth quarter. Signaturefd LLC now owns 5,886 shares of the medical instruments supplier’s stock valued at $380,000 after buying an additional 1,425 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its stake in shares of Baxter International by 3.9% in the fourth quarter. Guggenheim Capital LLC now owns 781,380 shares of the medical instruments supplier’s stock valued at $50,509,000 after buying an additional 29,668 shares in the last quarter. Institutional investors own 83.44% of the company’s stock.
BAX has been the topic of a number of research reports. Piper Jaffray Companies restated an “overweight” rating and set a $77.00 price target on shares of Baxter International in a research note on Thursday, May 31st. Stifel Nicolaus raised their price target on Baxter International from $71.00 to $72.00 and gave the stock a “hold” rating in a research note on Monday, April 30th. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a research note on Wednesday, April 11th. Finally, ValuEngine upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $73.25.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.